AbbVie annual total debt
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Total Debt Growth & History (ABBV)
AbbVie's total debt was $65.88B for fiscal 2025.
View full AbbVie company overviewAbbVie annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $65.88B | −$2.14B | −3.14% |
| 2024 | 2024-12-31 | $68.02B | $7.73B | +12.83% |
| 2023 | 2023-12-31 | $60.29B | −$3.90B | −6.08% |
| 2022 | 2022-12-31 | $64.19B | −$13.37B | −17.24% |
| 2021 | 2021-12-31 | $77.56B | −$9.47B | −10.88% |
| 2020 | 2020-12-31 | $87.03B | $19.94B | +29.72% |
| 2019 | 2019-12-31 | $67.09B | $30.48B | +83.25% |
| 2018 | 2018-12-31 | $36.61B | −$357.0M | −0.97% |
| 2017 | 2017-12-31 | $36.97B | $503.0M | +1.38% |
| 2016 | 2016-12-31 | $36.47B | $5.20B | +16.63% |
| 2015 | 2015-12-31 | $31.27B | $16.71B | +114.85% |
| 2014 | 2014-12-31 | $14.55B | $242.0M | +1.69% |
| 2013 | 2013-12-31 | $14.31B | −$342.0M | −2.33% |
| 2012 | 2012-12-31 | $14.65B | — | — |
AbbVie quarterly total debt
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $62.48B | −$6.03B | −8.81% |
| Q1 2026 | 2026-03-31 | $64.53B | −$1.59B | −2.40% |
| Q4 2025 | 2025-12-31 | $65.88B | −$2.14B | −3.14% |
| Q3 2025 | 2025-09-30 | $66.76B | $8.25B | +14.10% |
| Q2 2025 | 2025-06-30 | $68.52B | $10.47B | +18.03% |
| Q1 2025 | 2025-03-31 | $66.12B | $2.31B | +3.62% |
| Q4 2024 | 2024-12-31 | $68.02B | $7.73B | +12.83% |
| Q3 2024 | 2024-09-30 | $58.51B | $2.88B | +5.17% |
| Q2 2024 | 2024-06-30 | $58.05B | $2.24B | +4.01% |
| Q1 2024 | 2024-03-31 | $63.81B | $4.51B | +7.61% |
| Q4 2023 | 2023-12-31 | $60.29B | −$3.90B | −6.08% |
| Q3 2023 | 2023-09-30 | $55.63B | −$4.78B | −7.91% |
| Q2 2023 | 2023-06-30 | $55.81B | −$5.21B | −8.53% |
| Q1 2023 | 2023-03-31 | $59.29B | −$4.24B | −6.68% |
| Q4 2022 | 2022-12-31 | $64.19B | −$13.37B | −17.24% |
| Q3 2022 | 2022-09-30 | $60.41B | −$13.66B | −18.44% |
| Q2 2022 | 2022-06-30 | $61.02B | −$13.23B | −17.82% |
| Q1 2022 | 2022-03-31 | $63.53B | −$10.66B | −14.37% |
| Q4 2021 | 2021-12-31 | $77.56B | −$9.47B | −10.88% |
| Q3 2021 | 2021-09-30 | $74.06B | −$8.27B | −10.05% |
| Q2 2021 | 2021-06-30 | $74.25B | −$7.87B | −9.58% |
| Q1 2021 | 2021-03-31 | $74.19B | $10.90B | +17.23% |
| Q4 2020 | 2020-12-31 | $87.03B | $19.94B | +29.72% |
| Q3 2020 | 2020-09-30 | $82.34B | $48.84B | +145.77% |
| Q2 2020 | 2020-06-30 | $82.13B | $49.80B | +154.05% |
| Q1 2020 | 2020-03-31 | $63.29B | $27.31B | +75.89% |
| Q4 2019 | 2019-12-31 | $67.09B | $30.48B | +83.25% |
| Q3 2019 | 2019-09-30 | $33.50B | −$5.99B | −15.16% |
| Q2 2019 | 2019-06-30 | $32.33B | −$1.76B | −5.17% |
| Q1 2019 | 2019-03-31 | $35.98B | $4.71B | +15.06% |
| Q4 2018 | 2018-12-31 | $36.61B | −$357.0M | −0.97% |
| Q3 2018 · Sep 30 | 2018-09-30 | $39.49B | $4.71B | +13.56% |
| Q2 2018 | 2018-06-30 | $34.09B | −$127.0M | −0.37% |
| Q1 2018 | 2018-03-31 | $31.27B | −$5.65B | −15.31% |
| Q4 2017 | 2017-12-31 | $36.97B | $503.0M | +1.38% |
| Q3 2017 | 2017-09-30 | $34.77B | −$2.51B | −6.73% |
| Q2 2017 | 2017-06-30 | $34.22B | −$3.60B | −9.53% |
| Q1 2017 | 2017-03-31 | $36.93B | $7.04B | +23.54% |
| Q4 2016 | 2016-12-31 | $36.47B | $5.20B | +16.63% |
| Q3 2016 | 2016-09-30 | $37.28B | $5.17B | +16.08% |
| Q2 2016 | 2016-06-30 | $37.82B | $10.71B | +39.48% |
| Q1 2016 | 2016-03-31 | $29.89B | $18.64B | +165.64% |
| Q4 2015 | 2015-12-31 | $31.27B | $16.71B | +114.85% |
| Q3 2015 | 2015-09-30 | $32.12B | $17.35B | +117.46% |
| Q2 2015 | 2015-06-30 | $27.12B | $12.39B | +84.20% |
| Q1 2015 | 2015-03-31 | $11.25B | −$3.14B | −21.80% |
| Q4 2014 | 2014-12-31 | $14.55B | $242.0M | +1.69% |
| Q3 2014 | 2014-09-30 | $14.77B | −$16.0M | −0.11% |
| Q2 2014 | 2014-06-30 | $14.72B | −$15.0M | −0.10% |
| Q1 2014 | 2014-03-31 | $14.39B | −$235.0M | −1.61% |
| Q4 2013 | 2013-12-31 | $14.31B | −$342.0M | −2.33% |
| Q3 2013 | 2013-09-30 | $14.79B | — | — |
| Q2 2013 | 2013-06-30 | $14.74B | — | — |
| Q1 2013 | 2013-03-31 | $14.62B | — | — |
| Q4 2012 | 2012-12-31 | $14.65B | — | — |
AbbVie total debt trends
Over the last five fiscal years, AbbVie's total debt decreased from $87.03B to $65.88B, a change of −$21.15B. The latest reported quarter, Q2 2026, shows $62.48B.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
FDA clears at-home Skyrizi induction for Crohn’s disease
AbbVie ($ABBV) received FDA approval for subcutaneous induction dosing of Skyrizi in adults with moderately to severely active Crohn’s disease. Patients can now begin treatment at home using an on-body injector, extending that delivery opti ...
AbbVie meets pivotal hidradenitis endpoint with lutikizumab
AbbVie ($ABBV) reported that lutikizumab met the main endpoint and all eight ranked secondary endpoints in the Phase 3 INTREPID trial for moderate to severe hidradenitis suppurativa. At week 16, 31.4% of treated patients achieved HiSCR75, c ...
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...
